Torrent Pharma shares hit 52-week high; here's why
The USFDA conducted the pre-approval inspection at the company’s oral-oncology manufacturing facility situated in Bileshwarpura, Gujarat from December 5 to December 11 last year.
usfda
March 2024
November 2023
October 2023
September 2023
July 2023
April 2023
January 2023
November 2022
Aurobindo Pharma shares rise 2% on USFDA approval for asthma drug
Aurobindo Pharma has received approval from USFDA to produce and trade Budesonide Inhalation Suspension
Cipla stock tanks 8% after USFDA warning over issues at MP unit
Warning letter stresses data integrity issues at company embedded with product complaints and microbial contamination
Biocon shares drop 6% after USFDA inspection of Malaysian unit
The OAI status may cause delay or withholding of pending product approvals or supplements from the facility, Biocon says
Strides Pharma surges 10% on USFDA's approval for Icosapent Ethyl capsules
Strides Pharma Global Pte Limited, Singapore, which is a wholly-owned subsidiary of Strides Pharma, has received approval for Icosapent Ethyl Capsules 0.5 gram and 1 gram, from the USFDA.
Zydus Lifesciences gets USFDA nod for cancer drug; stock hits 52-week high
The share price of the drugmaker has risen 92% in the last one year from its 52-week low of ₹340.60 touched on July 27, 2022.
Dr. Reddy's shares hit 52-week high as USFDA completes inspection of API plant
The pharma major received “zero observations” post the USFDA pre-approval inspection (PAI) and a routine GMP inspection at the Andhra Pradesh facility
Zydus Lifesciences gets USFDA nod for osteoporosis drug; stock hits 52-week high
The USFDA has allowed Zydus to manufacture and market Estradiol Transdermal System USP in the U.S; the drug will be produced at the group’s facility in Moraiya, Ahmedabad.
USFDA inspections to be less disruptive for Indian pharma sector: Report
Indian pharma companies have increasingly de-risked their operations by slowly and steadily increasing sales to non-US markets, says India Ratings and Research.
Cipla's Goa plant classified as 'Official Action Indicated' by USFDA; stock falls
USFDA may continue to withhold product approvals from this facility till the outstanding observations are resolved, says Cipla.
